NRx Pharmaceuticals Sued for Breach of Contract, Alleged Misrepresentation in Acquisition
NRXP has more than doubled off its 52-week low of $1.62 on light trading volume (0.2× avg).
Summary
Kadima Neuropsychiatry Institute has filed a lawsuit against NRx Pharmaceuticals, alleging breach of contract and misrepresentation related to an acquisition. The suit claims NRx warranted it had funds to close the deal while concealing a lack of committed financing. This follows NRx's recent Q1 'going concern' warning and a dilutive $22.3 million public offering in early June. The lawsuit seeks specific performance, which could force the company to complete a deal it may not be able to finance, adding significant legal and financial risk to a company already facing liquidity challenges.
At the time of this announcement, NRXP was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $155.6M. The 52-week trading range was $1.62 to $5.06. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.